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Deconstructing the Human Egg:
The FDA's Regulation of Scientifically
Created Babies
INTRODUCTION
In 1997, scientists cloned Dolly, the now famous Scottish
Sheep;' since then, animal cloning techniques have proceeded at a
rapid pace. 2 Dolly was a great technical achievement, presenting
scientists with the possibility of human cloning. Then in 1998,
scientists successfully cloned eight identical cow calves from a sin-
gle cow, 3 and several litters of mice.4 These mammalian clones
thus raised questions regarding the ethics, morality and safety of
human cloning. 5 This morality questioning resulted in a ban on
1. Dolly was the first mammal cloned from the transfer of a somatic cell's
DNA (the molecular basis of genes) into an enucleated egg cell. See Lori D. An-
drews, Is There a Right to Clone? Constitutional Challenges to Bans on Human
Cloning, 11 Harv. J.L. & Tech. 643, 644 (1998).
2. See Teruhiko Wakayama et al., Full-term Development of Mice from Enu-
cleated Oocytes Injected with Cumulus Cell Nuclei, 394 Nature 369, 373 (1998)
(stating that:
contrary to previous opinion, mammals can be reproducibly cloned from
adult somatic cells. Furthermore, we believe that the success of these ex-
periments in the mouse provides an amenable model with which to evalu-
ate the molecular mechanisms that regulate the reprogramming of
somatic cell genomes, genomic imprinting, embryonic genomic activation
and cell differentiation).
3. See Jeffrey Kiuger, How to Clone a Herd, Time, Dec. 21, 1998, at 63, avail-
able in 1998 WL 21378329 (explaining how two different types of cells were placed
into cow ova (without genes) and out of ten implanted embryos, eight calves were
born. However, no one knows how the Japanese scientists managed to produce
eight calves out of ten embryos).
4. See Michael D. Lemonick, Dolly Your History, by Making Dozens of Copies
of a Mouse Scientists Take Cloning One Step Closer to the Assembly Line, Time,
Aug. 3, 1998, at 64, available in 1998 WL 14834988 (stating that it was believed
that mice cloning would be more difficult than cloning humans because mice have
been "long believed to be among the worst candidates for cloning because their egg
cells are particularly delicate and their embryos develop so rapidly").
5. See National Bioethics Advisory Commission, Cloning Human Beings: Re-
port and Recommendations of the National Bioethics Advisory Commission, at I
(1997) [hereinafter NBAC Report].
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federal funds for human cloning by President Clinton.6 Congress
also attempted to quickly pass federal legislation under its spend-
ing or Commerce Clause authority.7 However, the executive and
congressional bans on federal funding for human cloning do not
inhibit the use of private research funds; adding to this problem,
Congress has not passed legislation under its Commerce Clause
authority that could prevent the dangers of privately funded re-
search.8 In fact, in 1998, Richard Seed, a physicist, proposed to
clone a human being with private funds as a way to aid infertile
women.9
On January 20, 1998, in response to the potential physical
risks to women and children, the Food and Drug Administration
(FDA) announced its intentions to regulate human cloning under
section 351 of the Public Health and Service Act (PHSA).10 Thus,
using this already existing Act to regulate tissue and cell-based
products, the FDA claimed that it could, in theory, regulate some
instances of somatic cell cloning (human cloning).11 The FDA pro-
posal to regulate cell and tissue-based products was intended to:
(1) prevent the use of contaminated tissue; (2) prevent mishan-
dling that might contaminate the tissue; and (3) ensure clinical
6. See id.
7. See Jennifer Cannon & Michelle Haas, The Human Cloning Prohibition
Act: Did Congress Go Too Far?, 35 Harv. J. on Legis. 637, 639 (1998) (citing 143
Cong. Rec. E607).
8. See id. at 645; Nicole Z. Dizon, Chicago Physicist Wants Money From
NASA for Cloning (last modified Nov. 18, 1998) <http://www.dailyregister.com/
archive1998/cloningll1898.html> (noting Richard Seed's claim that he and his
wife have volunteered as test models for human cloning. He will continue to at-
tempt cloning even if the federal government interferes because the federal gov-
ernment cannot regulate test experiments performed with the use of private funds.
His wife would carry an embryo that would be created by combining the nucleus of
one of his cells with a donor egg).
9. See Rick Weiss, Scientist Plans to Clone Humans, Wash. Post, Jan. 7,
1998, at A3, available in 1998 WL 2460652 (describing Seed as "a brilliant man ...
a little crazy ... and if anyone can make [human cloning] happen it would be
someone like Richard Seed").
10. See Rick Weiss, Human Clone Research Will be Regulated, Wash. Post,
Jan. 20, 1998, at Al, available in 1998 WL 2462936.
11. Somatic cells are cells of the embryo, fetus, child, or adult, having two sets
of chromosomes: a germ cell, in contrast, has one set of chromosomes. NBAC Re-
port, supra note 5, at 1 n.2. This type of cloning is the most controversial because
it involves "the creation of genetic replicas of existing or previously existing chil-
dren or adults." See N.Y. Task Force on Life and the Law, Assisted Reproductive
Technologies 391 (1998) [hereinafter N.Y. Task Force].
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safety for tissue that is more than minimally manipulated. 12 As
outlined above, the proposal could cover human cloning because
the cloning procedure involves cells that are more than minimally
manipulated. 13 Thus, according to the FDA, human cloning is a
form of cellular or genetic therapy that requires prior approval by
the FDA reviewers; any attempts lacking FDA approval would
therefore violate the law. 14 Under an approved proposal, anyone
who desires to legally attempt human cloning must first file a for-
mal application with the FDA and then undergo a lengthy re-
view.15 The million dollar question is who will attempt to clone a
human being and why. This Comment assumes that human clon-
ing could someday be considered an assisted reproductive technol-
ogy because the technology will inevitably become a valid
treatment for infertile couples.16
Many people, including infertility specialists, question the
FDA's decision to regulate human cloning since the FDA failed to
regulate assisted reproductive technology (ART), such as in vitro
fertilization (IVF) or intracytoplasmic sperm injections (ICSI),
when they were first developed. 17 However, some people believe
that the states should regulate human cloning. This is supported
12. See Food and Drug Administration, Proposed Approach to Regulation of
Cellular and Tissue-Based Products 6 (1997) [hereinafter FDA Proposal].
13. See Weiss, supra note 10, at Al; see also Sheryl Gay Stolberg, F.DA.
Stand on Cloning Raises Even More Questions, N.Y. Times, Jan. 21, 1998, at A15,
available in 1998 WL 5394533 (noting that in February of 1997, the FDA issued a
new guidance proposal governing cells and tissue products. Under this proposal
the FDA claims it has the authority to regulate cell or gene therapies that involve
"more than minimal manipulation" (MTMM) of human cells or tissue. Mr.
Feldbaum, the acting commissioner of the FDA, argued that "cloning, which in-
volves taking genetic material from one cell and inserting it into another, meets
the 'more than minimal manipulation standard'").
14. See Weiss, supra note 10, at Al; see also Stolberg, supra note 13, at A15
(quoting an unknown agent of the FDA as stating "'[wie regard this as a gene
therapy or a cell therapy or both, and these therapies are subject to FDA require-
ments that cover clinical trials'").
15. See Stolberg, supra note 13, at A15 (stating that because the FDA claims
human cloning involves more than minimum manipulation of cells, then "any sci-
entist who wants to create a genetic replica of a person will have to submit an
'investigational new drug application,' the same request that drug companies must
submit when they want to test a new medicine").
16. According to John Robertson, a professor of law and co-chair of the Ameri-
can Society for Reproductive Medicine (ASRM) Ethics Committee, human cloning
may soon become a valid treatment for infertile couples. See John A. Robertson,
Liberty, Identity, and Human Cloning, 76 Tex. L. Rev. 1371, 1373 (1998).
17. See Andrews, supra note 1, at 658 n.102.
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by evidence that some states have banned human cloning prior to
the FDA's proposed regulation.' These proponents of states'
rights argue that the only federal regulation of assisted reproduc-
tive techniques is a federal law requiring the monitoring of as-
sisted reproduction clinics using IVF.' 9 The FDA's delay has
caused inconsistency among the states' human cloning regulations
and confusion as to whether the FDA has authority to regulate
cloning.
This Comment examines: (1) the FDA's regulatory authority
over human cloning provided by section 351 of the Public Health
and Service Acts (PHSA), (2) the FDA's current inability to effec-
tively utilize that authority due to its own narrow proposal and (3)
the urgent need for the FDA to maximize its regulatory authority.
Part I of this Comment defines cloning and explains the cloning
procedure. This Part also considers the harm posed to women un-
dergoing and children created by the cloning procedure. Part II
examines the reasons supporting regulation of human cloning.
This Part describes the past problems caused by the lack of uni-
form assisted reproductive regulations. Part III explores the need
for uniform regulation to replace outdated and meaningless state
and congressional legislation.
For the FDA to regulate human cloning, a cloned embryo must
be considered a biological product under section 351 of the
PHSA. 20 Thus, Part IV explores the FDA's authority to regulate
human cloning, as dictated in section 351 of the PHSA's definition
of "biological products."21 The definition of "biological products" in-
cludes a more than minimally manipulated egg cell used for treat-
ing infertility, thus providing the support for FDA regulation.
18. See id. at 658 (citing Michigan and California as states that currently pro-
hibit cloning); NBAC Report, supra note 5, at 89.
19. See NBAC Report, supra note 5, at 88 (noting that 42 U.S.C-A. § 263a-1,
the Fertility Clinic Success Rate and Certification Act, "covers all laboratories and
treatments that involve manipulation of human eggs and embryos, and requires
that rates of success at achieving pregnancies be reported to the Department of
Health and Human Services (DHHS) for publication in a consumer guide"). This
statute only extends to the monitoring of ART; it does not require FDA approval
before a procedure can be used.
20. See Elizabeth C. Price, Does the FDA Have Authority to Regulate Human
Cloning?, 11 Harv. J.L. & Tech. 619, 624-25, 638-39 (1998); Andrews, supra note 1,
at 658.
21. See Public Health Service Act, 42 U.S.C. § 262(a) (1997).
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Specifically, this part demonstrates how banning federal funds will
not deter human cloning.22
This Comment concludes that the FDA has the authority to
regulate human cloning. However, the FDA undermines and re-
stricts its authority through its own cell and tissue based proposal.
The proposal could cover human cloning because the cloning proce-
dure involves cells that are more than minimally manipulated.
However, the proposal's primary concern with reproductive tissue
is to stop the spread of communicable diseases rather than to en-
sure clinical safety of more than minimally manipulated reproduc-
tive tissue.23 The FDA does not believe that there is a large risk of
harm from reproductive tissue failure to women.24 "Failure of re-
productive tissue generally does not have life-threatening or sys-
temic adverse effects except for fertility per se."25 Although
unstated in its proposal, the FDA implies that if the reproductive
transplant fails, the tissue is naturally rejected by the woman's
body with limited harm, in the form of a miscarriage; and not or-
gan failure which could lead to death. Therefore, the proposal cov-
ers only cells and tissues that come from a donor, however, it does
not require regulation of cells and tissue removed from the same
person or from that person's sexual partner. The FDA's concern
with only donated reproductive tissue is a catastrophic oversight in
the FDA's proposed regulation of cloning. This oversight provides
a loophole that could lead to misuse of cloning as an assisted repro-
ductive technique. The FDA needs to revise its current tissue and
cell based-products proposal to address all forms of cloning proce-
dures, including reproductive tissues and cells from a sexual part-
ner or oneself, and the products of these cells and tissues (embryos/
children).
I. HuMAN CLONING AND ITS PossmLE HARM
As aforementioned, scientists have successfully used the so-
matic cell cloning procedure on other mammals. However, this
procedure, if attempted on a human embryo, could cause unex-
pected side effects.
22. See Dizon, supra note 8.
23. See FDA Proposal, supra note 12, at 6.
24. See id. at 20.
25. Id.
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A. What is Human Cloning?
The scientists at the Roslin Institute in Scotland used somatic
cell cloning to create Dolly from an adult sheep.26 In theory, this
same procedure could be used to clone a human child from a
human adult.27 Essentially, the somatic cell process requires the
removal of an egg cell's DNA and the transfer of an adult cell's
nucleus into the egg.28 In other words, the DNA from the adult cell
replaces the fusion of sperm and egg during regular sexual repro-
duction.29 In the cloning procedure, scientists "depriv[e] the [re-
productive] cells of the full amount of nutrient-laden serum that is
naturally supplied and in effect cause[ I the cells to remain in the
beginning stages of the [reproductive] cell cycle." 30 This process
prevents the adult DNA (DNA from a fully developed human) from
replicating before the transfer into the egg cell is complete.31 Next,
scientists introduce an electric charge to the egg cell.3 2 This
charge fuses the adult DNA with the "unfertilized chromosome-ex-
tracted egg" (an egg without a nucleus).3 3 The cloned egg cell be-
26. See Jason T. Corsover, The Logical Next Step? An International Perspec-
tive on the Issues of Human Cloning and Genetic Technology, 4 ILSA J. Int'l &
Comp. L. 697, 706 (1998).
27. See Herbert Wray et al., The World After Cloning, U.S. News & World
Rep., Mar. 10, 1997, at 59, available in 1997 WL 8331693 (describing how infertile
couples could use cloning to create a child).
28. See Corsover, supra note 26, at 706. The following is a brief overview of
the genetic process that drives a cell to differentiate. Inside a cell is a nucleus
which contains genes composed of DNA. These genes tell the cell to produce pro-
teins. See Neil A. Campbell, Biology 247 (3d ed. 1993). As an organism grows after
fertilization, its cells develop, divide, differentiate and specialize by switching on
and turning off certain genes inside their nuclei. See id. at 230. All somatic cells
have the same genes in the nucleus; the type of genes activated depends on the
type of cell. See id at 234-35. The role of cell types (muscle, liver, and skin) de-
pends on the specialized proteins. See id. at 316. With the right cellular environ-
ment and with the correct regulatory molecules, it should be possible to turn on or
off genes in cells. See Davor Solter, Dolly is a Clone-and no Longer Alone, 394
Nature 315-16 (1998). It was once believed that if genes were turned off, it was
permanent, but Dolly revealed the process was reversible. Michael J. McDaniel,
Regulation of Human Cloning. Implications for Biotechnological Advancement, 32
Val. U. L. Rev. 543, 545-46 (1998). The manipulation seemed to enable the nu-
cleus-free egg to reprogram the new nucleus. See id.
29. See Corsover, supra note 26, at 706 (citing Elizabeth Pennisi & Nigel Wil-
liams, Will Dolly Send in the Clones, Science, Mar. 7, 1997, at 1415).
30. Id.
31. See id.
32. See id.
33. Id.
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gins the process of cellular division and differentiation, just as if it
were a fertilized egg containing both male and female genetic
materials. 34
To understand the potential threats of human cloning, one
must realize that cloning is dramatically different from a normal
assisted reproductive technology such as in-vitro fertilization
(JVF). In IVF, sperm fertilizes a new egg cell, and after about two
and one half days in a petri dish, the fertilized egg (embryo) is
placed in the uterus.36 IVF is the same as regular human concep-
tion, except in IVF, conception occurs outside of the human body.36
Conversely, human cloning, unlike IVF and "traditional" sexual re-
production, is a complicated procedure with unknown risks and
dangers, which scientists should not rush into clinical use.37
B. Risks of Human Cloning
Human cloning raises some potentially dangerous health is-
sues. Specifically, this difficult procedure can deform the DNA and
the egg by subjecting them to unnatural treatment. First, an enor-
mous number of miscarriages would occur through the cloning pro-
cedure.38 The accepted data demonstrates that cloning a human
has a "high likelihood of failure and a consequent high rate of mis-
carriage, and.., unknown risks of developmental abnormalities in
the offspring."39 Second, there is a distinct chance of deformed
births. When the scientific team attempted to create Dolly, many
of the sheep were born with deformities and died quickly thereaf-
34. See Michael Broyde, Cloning People: A Jewish Law Analysis of the Issues,
30 Conn. L. Rev. 503, 510 (1998).
35. See N.Y. Task Force, supra note 11, at 57 (noting that at this time, the
embryo has only made four to eight cellular divisions and then the embryo is trans-
ferred into the uterus of the woman, via a long sterile tube connected to a syringe
on one end. The procedure requires no anesthesia for the patient. Overall, the
stress on the embryo is minimal).
36. See id. at 51 (noting that IVF "refers to the union of sperm and egg in a
laboratory dish, literally 'in glass' rather than inside the body").
37. In 1998, Richard Seed, a physicist, proposed to clone a human being. See
Weiss, supra note 9.
38. See Andrews, supra note 1, at 652 (citing Dr. Wilmut, the scientist who is
responsible for Dolly, when he stated that "'with people, the possibility of 276 fail-
ures, many of which would involve miscarriages, sounds horrific and raises huge
ethical barriers'").
39. Bonnie Steinbock, The NBAC Report on Cloning Human Beings, 38
Jurimetrics J. 39, 40-41 (1997).
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ter; Dolly was the first survivor out of 277 attempts.40 The human
cloning procedure would use differentiated human DNA (which al-
ready contain a full set of genes). As a result, this DNA may have
acquired genetic mutations and could produce deformities. 41 An
adult nucleus has already completed forty-five cell divisions, and
may have accumulated genetic disease and mutations, which
would be transferred upon implantation into an undifferentiated
egg cell.42 Thus, when a cell's genes are reactivated to differenti-
ate a new egg cell, many hidden risks exist.
43
Even if the adult DNA does not contain mutations before the
procedure begins, it is still likely that the overall process of cloning
will cause stress on the egg and create genetic deformities in the
cloned child. In order to produce a clone, the nucleus of the egg cell
is stressed through bio-chemical processes. 44 First, "using an elec-
trical charge, the researchers . . . fuse[d] the donor cell with an
unfertilized chromosome-extracted egg."45 Second, "this new fused
egg [is] now provided with a full complement of DNA from the orig-
inal donor... and the egg [begins] to divide and develop."46 There-
fore, the added stress to a rapidly dividing cell during development
creates a high potential for cellular deformity. 47
40. See Andrews, supra note 1, at 652 (citing Nick Thorpe, Scientists Baffled
by Oversized Sheep Clones, Scotsman, July 28, 1997 at 1; Steven Connor, "Giant"
Lambs Put Future of Cloning in Doubt, Sunday Times (London), July 27, 1997, at
5).
41. See id. at 650 (noting that many top geneticists believe that using aged
cells to create a new life might not facilitate the average life span of most humans.
In fact, cloning might create a new child that is as old as the adult DNA that
differentiated the egg cell. Thus, if a thirty-year-old person's DNA was used to
differentiate the egg cell, the resulting child would age at the same rate as the
thirty-year-old person. This has lead one geneticist to state that "to avoid subject-
ing human clones to premature aging and the potential harms associated with
aged cells" more animal testing must be done before cloning is used on humans).
42. See id. (noting that "[a]n adult cell which has already been differentiated
contains a complete complement of genes, but only a small proportion are activated
in order to do specialized task of that cell. Activating the slumbering genes may
reveal hidden mutations").
43. See id.
44. See Corsover, supra note 26, at 707.
45. Id. (citing Pennisi & Williams, supra note 29, at 1415).
46. Id. (citing Clive Cookson, FT Guide to: Cloning, Fin. Times, Mar. 3, 1997,
at 10).
47. See id. at 708.
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Successful animal testing does not guarantee positive results
for human cloning.48 One variance lies in gene activation.49 If
DNA replication (gene activation) starts before the transfer of
adult DNA into the undifferentiated egg, then there will be an ex-
cess of DNA. Thus, this excess DNA will likely cause chromosome
damage.50
Sheep genes are slow to activate5 l in the nucleus during their
first few hours of development.5 2 In humans, gene activation is
faster than in sheep, but slower than gene activation in mice.5 3
For example, mice genes activate at the two-cell stage (fast);
human genes activate at the four-eight cell stage (slower); and,
sheep genes activate at the eight-sixteen cell stage (slowest).5 4
Some scientists believe that the newly cloned mice offer proof that
scientists could successfully clone humans. 55 Mammals were be-
lieved to be more difficult to clone than humans because of the
shorter gene activation times.5 6 However, no animal has been
cloned with the same gene activation time as a human.5 7 Thus,
48. See Ricki Lewis, Mammalian Cloning Milestone, Mice from Mice from
Mice, The Scientist, Aug. 17, 1998, at 1, 7 (stating that "cloning... sheep and mice
are about as far apart as you can get among placental mammals") (citing Lee Sil-
ver explaining the cell stages).
49. See id.
50. See Robert Edwards, Remarks at Chicago-Kent College of Law: Institute
for Science, Law and Technology Changing Conceptions Conference "Creating the
next generation: scientific developments" (visited Oct. 17, 1999) <http://www.ken-
tlaw.edu/islt/cc/edwards.html>.
51. A gene is a specific sequence in a DNA molecule that performs a specific
function in the body, such as creation of the pigments and fibers of the body. In the
cell, activated genes control the cell's performance of specific functions. See Helena
Curtis, Biology 268 (5th ed. 1989).
52. See id.
53. See Lewis, supra note 48, at 7.
54. See id. The following is a brief explanation of how the meiotic divisions
take place in humans:
Formation of the ovum begins with the growth of an oogonium into a pri-
mary oocyte. In the first meiotic division, this cell divides into a secon-
dary oocyte and a polar body. The first meiotic division begins in the
human female during the third month of fetal development and ends at
ovulation, which may take place 50 years later. The second meiotic divi-
sion, which produces the egg cell and a second polar body, does not take
place until after the fertilizing sperm cell has penetrated the secondary
oocyte.
Curtis, supra note 51, at 258.
55. See Lewis, supra note 48, at 7.
56. See id.
57. See id.
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cloned mice offer no assurance that the cloning process will achieve
the desired results for humans. Rather, uncertainty, fears of mu-
tated human "clones" and unnecessary deaths loom over human
cloning.
As for Dolly, a successfully cloned sheep, researchers have re-
cently determined that she may be susceptible to premature aging
and disease because her genetic source was taken from a six-year-
old sheep.58 All chromosomes are "capped" with tips called
telomeres. 59 These "caps" regulate a cell's life span and prevent
the genetic code from disassembling.60 As part of the aging pro-
cess, telomeres eventually break down and signal the cell to do the
same, leading to the cell's destruction.6 1 Dolly, an animal model
for cloning, has been found to have shorter telomeres than average
for a sheep Dolly's age.6 2 These findings further illustrate that the
cloning process should not be used on humans until scientists have
a better understanding of the consequences.
The Director of the National Institute of Health (NIH), Harold
Varmus, testified before Congress that animal cloning technology
is currently inapplicable to human cloning research. 63 Technical
questions exist, which can only be answered by continued animal
research.64 In fact, the recently cloned mice created more safety
questions for researchers because scientists created the mice
clones from different cells. By using cells from different parts of an
adult body, with each cell possibly causing different ramifications
in a cloned child's cellular development, scientists will encounter
great difficulty when monitoring the cloning process. 65 The safety
of surrogate mothers (who will be subjected to the imperfect c1on-
58. See Dolly's DNA Shows Signs of Decay: Using 6-Year-Old as Genetic
Source Could Mean Earlier Death for Clone, USA Today, May 27, 1999, at 2D,
available in 1999 WL 6843925.
59. See id.
60. See id.
61. See id.
62. See id.
63. See Andrews, supra note 1, at 649 (citing Paul Recer, Sheep Cloner Says
Cloning People Inhumane-Senator Disagrees, Associated Press Pol. Serv., Mar.
13, 1997, available in 1997 WL 2508493).
64. See id.
65. See Lewis, supra note 48, at 7 (noting that the scientists who cloned Dolly
used a mammary gland cell's nucleus, while the scientists who cloned Cumulina,
the mouse, used three types of cumulus cells (cumulus cells are a type of cells that
surround an oocyte (a developing egg), but are not egg cells)).
DECONSTRUCTING THE HUMAN EGG
ing procedures) is of great concern.68 Women will be subjected to
experimentation, unless continued animal research, as well as reg-
ulation of human cloning (by the FDA) are made mandatory for
their safety.67 The FDA should restrict cloning until this proce-
dure is made as safe as possible for women and children.
IL THE NEED FOR REGULATION
The possibility of human cloning presents a need for regula-
tion. When compared to IVF and other similar assisted reproduc-
tive techniques, the need for FDA regulation of cloning is apparent.
Regulation is required due to: (1) the current business-oriented ap-
proach taken towards medicine; (2) doctors' tendencies in similar
IVF situations to boost success rates;68 (3) the lack of regulations
for administrators of similar assisted reproductive programs;69 (4)
assisted reproduction doctors' failure to follow professional guide-
lines;70 and (5) the lack of avenues for redress for those injured by
negligently performed assisted reproductive practices. 7 ' For these
reasons, the FDA must take actions to regulate cloning.
A. Modern Medicine Becomes a Business
Many infertility practitioners are becoming more business-ori-
ented than medically-oriented. 72 This field of medicine (ART pro-
grams that someday might offer cloning) has become a billion-
dollar annual business. 73 Doctors are choosing to provide
whatever procedure the patient desires (so long as they can pay),
rather than advance professional and ethical standards concerning
66. See Lori D. Andrews et al., ART into Science: Regulation of Fertility Tech-
niques, 281 Science 651, 652 (1998).
67. See id.
68. See George J. Annas, Human Cloning: A Choice or an Echo?, 23 U. Dayton
L. Rev. 248, 258 (1998) (noting that "bio-ethics communities have consistently un-
derestimated the power of the market forces and commercialism to shape the de-
mand for and uses of new reproductive technologies"); N.Y. Task Force, supra note
11, at 398.
69. See N.Y. Task Force, supra note 11, at 410 (stating that "there is no com-
prehensive federal regulation of assisted reproduction programs").
70. See Rick Weiss, Fertility Innovation or Exploitation?, Wash. Post, Feb. 9,
1998, at Al, available in 1998 WL 2466726.
71. See Andrews, supra note 66, at 651.
72. See Annas, supra note 68, at 258.
73. See id. at 258, 263-64.
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infertility practices.74 When considering new assisted reproductive
techniques, such as IVF and human cloning, one can only hope
that infertility doctors will ensure that the procedure is completely
safe before using it on their patients. Unfortunately, this was not
the case with IVF. Practitioners used the IVF procedure on women
for years before using it on monkeys. 75 This has led some embryol-
ogists to ask, who were the research models? 7 6
If fertility doctors wish to attempt an innovative and unproven
technique like human cloning, nothing would stop them except
sporadic legislative bans. 77 In fact, the FDA's proposed cloning
regulation would only act as a deterrent. Although the success
rates and published statistics may dissuade potential patients,
scientists/doctors who perform human cloning, like doctors per-
forming IVF, may fail to inform them of low success rates.78 Thus,
patients will undertake the procedure regardless of the results.79
One IVF provider has already suggested that "even though the
cloning success rate is low (1 in 277 as in the Dolly experiment),
this should not be a deterrent since all new reproductive technolo-
gies have low success rates." 0
74. See id.
75. See Andrews, supra note 66, at 652 (citing D.P. Wolf& M.M. Quigley, His-
torical Background and Essentials for a Program in In Vitro Fertilization and Em-
bryo Transfer, in Human In Vitro Fertilization and Embryo Transfer 3-4 (D.P.
Wolf & M.M. Quigley eds. 1984)).
76. See id. (footnotes omitted).
77. See id. at 651.
78. See N.Y. Task Force, supra note 11, at 163 (citing National Advisory Board
on Ethics in Reproduction, NABER Identifies Ethical Issues Raised by Increased
Use of Micromanipulation Techniques, 1 NABER Report 5 (1995). ("The National
Advisory Board on Ethics in Reproduction (NABER) has identified several ethical
issues raised by the introduction of ICSI, including a rush to offer the technique
based on its reported success despite the fact that it takes time to learn to perform
it with any proficiency").
79. See id. at 161 (citing L. Brown et al., Our Miracle Called Louise: A Par-
ent's Story (1979) (quoting a client of an ART saying "I don't remember Mr. Steptoe
saying his methods of producing babies had ever worked and I certainly didn't ask.
I just assumed that hundreds of children had already been born through being
conceived outside their mother's wombs").
80. See Andrews, supra note 66, at 651 (citing P. Kendall & W. Neikirk, Clon-
ing Breakthrough a Large Step on Much Longer Road, Chi. Trib., Feb. 25, 1997, at
Al). See also Jean Macchiaroli Eggen, The "Orwellian Nightmare" Reconsidered: A
Proposed Regulatory Framework for the Advanced Reproductive Technologies, 25
Ga. L. Rev. 625, 634 (1991) (discussing the IVF procedure).
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Even today, the success rates of IVF, gamete intrafallopian
transfer (GIFT)8' and zygote intrafallopian transfer (ZIFT),8 2
range from 22.3% to 27.7%: not much higher since their discovery
over 10 years ago (slightly above 20%).83 When the Center for Dis-
ease Control (CDC) published this statistical data from 281 as-
sisted reproductive programs in 1995, many fertility doctors told
patients not to believe the statistics.84 The CDC success rates
were reported without a system of verification and the statistics
may not take into account clinics that handle tougher cases.85
These "statistics are self-reported. No one systematically audits
clinics to make sure they are telling the truth."8 6 Thus even these
statistics will not prevent human cloning if the doctors wish to ex-
periment on their patients.
In fact, some fertility doctors have been accused of attempting
risky procedures to boost success rates.8 7 Fertility clinics may
even deflate originally reported success rates of particular assisted
reproductive techniques when they want to improve the appear-
ance of the new technique or introduce a new technique to their
patients.8 " At some point, fertility doctors may raise their success
81. GIFT is a procedure that removes eggs from the ovary, combines them
with sperm, and uses a laparoscope to place the unfertilized eggs and sperm into
the fallopian tubes through surgery. See N.Y. Task Force, supra note 11, at 60.
82. ZIFT is a procedure in which eggs are collected from an ovary and fertil-
ized in the lab and uses a laparoscope to place the zygote (fertilized egg) into the
fallopian tubes through surgery. See id. at 62-63.
83. See Center for Disease Control and Prevention et al., 1995 Assisted Repro-
ductive Technology Success Rates (visited Oct. 20, 1999) <http://www.cdc.gov/
nccphp/drh/arts/fig7.htm>.
84. See Catherine Winter, The Fertility Race: Medical Specialty or Baby In-
dustry (visited Oct. 20, 1999) <http'//www.msnbc.conx/news/140296.asp?cpl=l.>.
85. See N.Y. Task Force, supra note 11, at 399 (citing P.A.L. Lancaster, Regis-
ters of In-Vitro Fertilization and Assisted Conception, 11 Human Reprod. 89, 93
(1996)) (noting that some ART programs have patient selection criteria used to
enhance a program's reported success rates).
86. See Winter, supra note 84.
87. See id. at 398 (citing F. Olivennes & R. Fryman, "The AR.T. of Embroi-
dery," 11 Human Reprod. 697, 697-99 (1996)). The N.Y. Task Force quoted one
commentator stating that "it is almost always possible to achieve impressive suc-
cess rates in this manner: 'All centres have known some marvelous series where
for a couple of weeks, or even months, one pregnancy follows another and for such
a period the success rate per oocyte retrieval amounts to 60%.'" Id. (quoting R.
Schoysman, Plea for Realism and Honesty in Results of Infertility Treatment, 11
Human Reprod. 696 (1996)).
88. See id. at 398-99 (noting one example where a "practitioner widely re-
ported pregnancy rates of 32 percent using standard IVF in couples with male
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rate through human cloning, but for now this procedure is far too
risky when compared with current assisted reproductive tech-
niques. It is due to this high risk factor that regulation is
necessary.
B. Similar Assisted Reproductive Programs Lack Regulations
Many medical professors are outraged by the lack of regula-
tions in the fertility field. Brooks A. Keel, an obstetrics and gyne-
cology professor said, "'[a] fertility doctor can literally set up a
laboratory in his garage and have his son or daughter who might
have a bachelor's degree to run it, and it would be perfectly legal,
... and [a] woman gets more regulatory oversight when she gets
tattoo than when she gets IVF.' 8s 9 Larger fertility centers follow
federal standards more often than smaller clinics, which are cut-
ting corners to break into the field.90 Although regulation is
needed, doctors claim, "it would be unusual and inappropriate to
impose federal regulation on a specific branch of medicine," espe-
cially reproductive technology, which has not previously been regu-
lated.91 Unfortunately, too often this branch of medicine has
rushed risky procedures into practice because of the strong desire
to have successful results.
Researchers may be justified in treating terminally ill patients
with risky, innovative procedures because these patients expect to
die from their illness regardless of treatment. However, research-
ers are not justified in the risks taken with human cloning because
these patients are not being treated for a life threatening illness.92
factor infertility; when the same practitioner began to use intracytoplasmic sperm
injection (ICSI), the pregnancy rate with standard IVF for couples with male factor
problems were said to be less than 5 percent").
89. Weiss, supra note 70, at Al (quoting Brooks A. Keel). "We have in many
respects far better protection for hamsters than for human fertility patients .... "
Id. (quoting R. Alta Charo).
90. See id. See also Annas, supra note 68, at 258 (stating that medicine has
become a business and advertising creates incentives to supply the demanded ser-
vice. If a person has the money, she can find a willing seller).
91. Weiss, supra note 70, at Al. This contradicts Sauer's earlier point that
"[wie don't really have a public policy for fertility patients in this country. I wish
we did." Id. Sauer would rather have the American Society for Reproductive
Medicine (ASRM) regulate this field. See id. Many fertility clinics do not follow
the ASRM standards and if the ASRM tried to regulate cloning, it is likely that
fertility clinics will not follow its regulations of cloning. See infra pp. 280-81.
92. See NBAC Report, supra note 5, at 64. The ASRM Commission believes
that without further animal testing, standard practice in the biomedical and
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All reproductive doctors and researchers are not created equal.
Many unqualified medical personnel will inevitably attempt to
clone their patients.93 Richard Seed is a good example. Seed, who
does not have a medical degree, intends to clone himself by placing
his wife at risk with this premature procedure.9 4
In addition to unqualified doctors, concern exists regarding the
facilities where doctors perform assisted reproductive procedures.
Presently, the facilities offering IVF procedures range "from large
university medical complexes to a single doctors office and the pro-
fessional qualifications of those offering the procedure are equally
disparate," because no regulatory body controls clinical IVF.95 Due
to the unidentified risks and dangers associated with human clon-
ing, society must take a stand and prevent the same doctors who
perform IVF in "offices" resembling car garages from attempting to
clone a human being.96
C. The Failure of Assisted Reproduction Doctors to Follow
Professional Guidelines
A large number of the reproductive clinics that use IVF and
other assisted reproductive techniques, fail to follow professional
guidelines. 97 The possible addition of cloning compounds this
problem. The American Society for Reproductive Medicine
(ASRM), which sets clinical guidelines, strongly opposes human
clinical fields would never tolerate doctors performing this procedure on humans.
See id.
93. See Annas, supra note 68, at 265 (stating that:
[i]f it is true that market values have been de facto incorporated into pro-
fessional medical values (and are often indistinguishable), then profes-
sional ethics and practice standards provide no public protection... [wie
must then turn to governmental regulation to "manage" medicine's mar-
ket competition in research related to new reproductive technologies, as
well as clinical practice itself).
94. See Dizon, supra note 8.
95. See Jennifer Gunning & Veronica English, Human In Vitro Fertiliza-tion
168-69 (1993) (stating that there "is no regulatory body for clinical IVF though
guidelines, setting out minimal standards and making recommendations for cer-
tain procedures, have been issued").
96. See supra note 89.
97. The ASRM has published guidelines for the number of eggs that may be
safely implanted into a woman during procedures such as 1VF. See N.Y. Task
Force, supra note 11, at 154.
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cloning on ethical grounds. 98 However, many clinics do not follow
the ASRM guidelines.99 For example, the ASRM issued profes-
sional practice guidelines dictating the number of transferable em-
bryos per IVF procedure. Although the guidelines recommend that
doctors transfer an average of three embryos per IVF procedure, on
average, doctors are transferring four.' 00 Any increase in that
number exponentially increases the risk to the mother and
offspring. 101
Despite ASRM recommendations, practitioners still offer and
therefore risk a patient's health through treatments that create
multiple births. In fact today, many patients request that practi-
tioners implant more embryos. 10 2 Reproductive doctors fail to fol-
low the guidelines because the more implants they use, the greater
the success rates for the procedure. 10 3 Although the American
Medical Association (AMA) strongly opposes money back guaran-
tees, many fertility clinics still make such offers because every
child born is another dollar made.' 0 4 One fertility specialist
claims, "you get a baby, or your money back."' 0 5 Monetary goals
illustrate why the reproductive doctors do not follow standards dic-
98. See Annas, supra note 68, at 265 (stating that cloning was the first repro-
ductive technique that the ASRM has opposed. It is unusual for the ASRM to op-
pose a reproductive technique. If any good can come from a reproductive
technique, the ASRM believes that it should not be outlawed).
99. See id.
100. See N.Y. Task Force, supra note 11, at 154 (noting that "published reports
suggest that this particular guideline is not being observed closely"). In 1994, over
half of the ART programs in New York State did not meet the ASRM's standards.
See id. The reports revealed high amounts of triplets, four of seventeen programs
resulting quadruplets, and three of the programs having five or more children. See
id.
101. See id. "Multiple gestations involve significant risks. One in ten infants
from multiple gestations dies before reaching twelve months of age and survivors
are far more likely than singletons to suffer complications leading to lifelong disa-
bility.". See id. at 151 (citing J.A. Martin et al., Triplet Births: Trends and Out-
comes, 1971-1994, in 21 no. 55 Vital Health Statistics 10 (Hyattsville, MA:
National Center for Health Statistics, 1997).
102. See id. at 153. Practitioners argue that limiting embryos transferred per
cycle would lower the per-cycle chance of pregnancy, something that many infertile
people could not pay for. See id.
103. See id. at 171 (calling for practitioners to eliminate the likelihood of multi-
ple births, even if the other options reduce the possibility of a woman becoming
pregnant).
104. See id. at 426 (noting that money back guarantees may cause fertility clin-
ics to take risks in order to increase the likelihood of pregnancy).
105. Winter, supra note 84.
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tating maximum numbers of implants. Fundamentally, it would
be bad for business.
D. No Redress for Injuries Caused by Reproductive Practices
In addition to placing patients at risk, human cloning offers no
redress for patients injuries. Cloning, like existing assisted repro-
ductive techniques, is not covered by health insurance.'06 Other
medical services and insurance providers require proof of efficacy
before reimbursing the patient for the procedure.' 0 7 Medical mal-
practice litigation, which serves as a quality control for other
health care, does not work as well in the assisted reproductive
field.108 Because of the high failure rate, the patient usually never
knows whether the failure was caused by negligence. 10 9 Even
though a child may hold an independent right to sue for injuries
caused by premature use of a risky technology,' 10 the courts are
reluctant to find doctors negligent for trying risky procedures."'
The FDA must regulate risky assisted reproductive procedures
such as human cloning, because of doctors' business-like approach
to infertility ethics and the intentionally unsafe methods spon-
sored by privately funded scientists. Thus, the FDA needs to pro-
mulgate a uniform standard for innovative assisted reproductive
techniques involving more than minimum manipulation of cells or
tissue. If the FDA continues to ignore the real dangers associated
106. See Andrews, supra note 66, at 651.
107. See id.
108. See N.Y. Task Force, supra note 11, at 102-03.
109. See Andrews, supra note 66, at 651 (stating that "[r]isk to the children
may not be discernible for many years, which may be past the period of time a
statute of limitations on a legal suit has run").
110. See N.Y. Task Force, supra note 11, at 103 (citing Procanik v. Cillo, 478
A.2d 722 (N.J. 1984); Harbeson v. Parke-Davis, 656 P.2d 483 (Wash. 1983); Turpin
v. Sortini, 643 P.2d 954 (Cal. 1982)).
111. See Andrews, supra note 66, at 651. (noting that some "courts have been
reluctant to impose liability on medical providers and laboratories for children
born with birth defects where the child would not have been born if the negligent
act had been avoided"). Some courts have not recognized a wrongful birth cause of
action, because the courts have not found doctors to be the cause of genetic disor-
ders. See Liddington v. Burns, 916 F. Supp. 1140 (W.D. Okla. 1996); see also At-
lanta Obstetrics & Gynecology Group v. Abelson, 398 S.E.2d 557 (Ga. 1990);
Wilson v. Kuenzi, 751 S.W.2d 741 (Mo. 1988); Azzolino v. Dingfelder, 337 S.E.2d
528 (N.C. 1985). As a result, the courts are actually backing doctors who use risky
procedures instead of finding them liable for the resulting birth defects.
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with the cloning process, inevitably tragic mistakes will occur and
many innocent people will be hurt.
III. REGULATIONS CURRENTLY COVERING HUMAN CLONING
Scientists could begin experimenting with human cloning in
the near future because of loopholes created by inconsistent state
and federal cloning bills. When it comes to policing themselves,
many fertility doctors and clinics fail to follow or enact guidelines
meant to protect the health and safety of their patients. The FDA
proposed cloning regulation would protect most United States citi-
zens from this very risky, experimental procedure. By examining
the problems with existing and proposed federal cloning regula-
tions, as well as existing state cloning regulations, this section con-
cludes that the state regulations, although a step in the right
direction, are inadequate to protect the public. Thus, it is impera-
tive that the FDA create uniform regulation for human cloning to
remedy the existing discrepancies.
A. Federal Regulations are Inadequate to Protect Against
Human Cloning
Congress had already banned federal funds for human embryo
research, as opposed to human cloning, prior to the birth of
Dolly.112 However, the restriction on federal funds for embryo re-
search will not stop privately funded institutions from cloning
humans. 113 Existing federal laws banning human cloning re-
search have also failed to assure that cloning will not take place in
the private sector. In an effort to eliminate embryo research, Con-
gress banned Fiscal Year 1996 and 1997 funds appropriated to the
Departments of Labor, Education and Health and Human Serv-
ices." 4 Congress' overall intent was to eliminate all federal fund-
ing for research to perfect methods for cloning humans." 5
112. See Steven Benowitz, Embryo Research Editorial Sparking Renewed De-
bate, The Scientist, June 24, 1996, at 6 (citing how in December 1994, Congress
would allocate no federal funding to create human embryos exclusively for re-
search purposes).
113. See Andrews, supra note 1, at 670 (noting that federal regulation "based
on the federal spending power is insufficient to reach research in the private
sector").
114. See NBAC Report, supra note 5, at 89 (citing P.L. 104-91, 104-208).
115. See id.
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Still, these restrictions prohibit only federally funded re-
search. Even if the human embryo research ban extended to a
cloned embryo created for implantation, privately funded universi-
ties, institutions or scientists could still attempt human cloning,
albeit, without federal funds.116 Thus, presently there is limited
federal oversight of privately funded scientists like Richard Seed,
who are willing to attempt human cloning, regardless of whether
public funding is available. 117
As aforementioned in Part II, denying federal funds to repro-
ductive clinics may have actually jeopardized the safety of clinic
patients. Congress does not require fertility clinics to follow fed-
eral regulations if they do not receive federal funds. Human clon-
ing could become another assisted reproductive technique, such as
IVF, which receives no federal funding.118 The federally regulated
institutional review boards (IRBs), 1"9 which govern all risky re-
search performed on human subjects, such as cloning, are only
present at institutions receiving federal funding.1 20 Thus, since
fertility clinics do not receive federal funding, IRBs cannot review
their innovative procedures. In fact, one rarely finds an institu-
tional review board in the fertility field. 121
Many of Congress' proposed bills to ban human cloning re-
strict federal funding, but allow cloning to occur in the private sec-
tor. For example, Congressman Vernon H. Ehlers' proposed bill
116. See id.
117. See Dizon, supra note 8 (discussing Richard Seed's willingness to use pri-
vate funds to attempt cloning. Such action would thwart any federal government
interference because the federal government cannot regulate test experiments per-
formed by private funds).
118. See Gunning & English, supra note 95, at 167 (stating that "[tihere has
been an effective moratorium on Federal funding for embryo research since 1975
when the Department of Health Education and Welfare (now Department of
Health and Human Services, DHHS) published regulations for the protection of
human subjects of research").
119. IRBs ensure that (1) human subjects are not exposed to harmful experi-
ments and (2) have given consent. See NBAC Report, supra note 5, at 88 (citing 45
C.F.R. § 46 (1997)).
120. See id.
121. See Andrews, supra note 66, at 651.
[WIhere the Board so establishes a class of applications or proposals
which must be submitted, no application or proposal within the class may
be funded by the Department or any component thereof until the applica-
tion or proposal has been reviewed by the Board and the Board has ren-
dered advice as to its acceptability from an ethical standpoint.
45 C.F.R. 46.204(c).
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H.R. 922,122 which prohibited federal funds to conduct or support
any project of research, including the use of human somatic cell
nuclear transfer technology to produce an embryo.' 23 Congres-
sional bill, S. 1602, would prohibit human cloning by invoking Con-
gress' Commerce Clause authority.124 However, it should be noted
that the Supreme Court, in United States v. Lopez, 125 limited Con-
gress' Commerce Clause authority to commercial areas of inter-
state commerce. 126 Whether medical procedures, such as human
cloning, could be considered a commercial activity is still debata-
ble. 127 Cloning is an activity that includes "personnel and patients
from a national market," and therefore should be considered a com-
mercial activity that Congress could regulate under the Commerce
Clause. 128 Thus, while Congress considers whether or not to regu-
late human cloning, the FDA must protect the public from the un-
known risks.
Some commentators suggest that Congress should rely on the
FDA to regulate human cloning until it is considered safe for
humans. Such action would require the FDA to draft regulation on
cells and tissues that "clearly delineates acceptable and unaccept-
able areas of research."129 These commentators believe that in the
rush to ban human cloning due to the large public protest against
the procedure, Congress was not concerned about the long-term
122. See H.R. 922, 105th Cong. (1997). Representative Ehlers has introduced
another human cloning bill, H.R. 923, which would make it unlawful for anyone
(privately or publicly funded) to clone a human. See H.R. 923, 105th Cong. (1997).
These bills have not been passed.
123. See Heidi Forster & Emily Ramsey, Legal Response to the Potential Clon-
ing of Human Beings, 32 Val. U. L. Rev. 433, 440 (1998) (citing 143 Cong. Rec.
H6714 (Aug. 1, 1997) (noting that the Committee on Science has altered the bill to
allow non-human cloning to proceed)).
124. See S. 1602, 105th Cong. (1998) (Section b of the proposed act states: "[ilt
shall be unlawful for any person or other legal entity, public or private" to clone
human beings) (emphasis added).
125. 514 U.S. 549 (1995).
126. See Andrews, supra note 1, at 674-75 (citing United States v. Lopez, 514
U.S. 549, 551 (1995)); Cannon & Haas, supra note 7, at 641. For an in-depth dis-
cussion of Congress' Commerce authority see Andrews, supra note 1, at 674-75.
127. See Andrews, supra note 1, at 675.
128. Id.
129. See Cannon & Haas, supra note 7, at 641 (noting that "[tihe fact that Food
and Drug Administration ("FDA") has claimed jurisdiction over human cloning
and has promised to prevent any attempt to clone a human being makes the need
to enact legislation less urgent").
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ramifications of these proposed bills on scientific research. 30
Whether Congress will regulate human cloning remains to be seen.
Evidently, Congress must be extremely careful when creating bills
to regulate human cloning.
Proposed federal bills 13 1 banning human cloning are similar in
that they ban the cloning process to create a baby, but then diverge
into separate regulatory schemes. They differ in their respective
definitions of cloning, sunset clauses (time limit for the cloning
ban) and in their permission to use cloned embryos for research
purposes. Dozens of medical organizations, biotechnology compa-
nies and distinguished scientists oppose Congressional bill S.
1601132 because it bans baby making, cloning human embryos and
research on cloned embryos. 133 This bill upsets scientists because
Congress has never before banned scientific or medical research. 134
Scientists prefer bill S, 1602,135 which would forbid them from im-
130. See id. at 636-38.
131. See S. 1611, 105th Cong. (1998), also labeled as S. 1602, 105th Cong.
(1998); S. 1601, 105th Cong. (1998), also labeled as S. 1599, 105th Cong. (1998);
H.R. 3133, 105th Cong. (1998); S. 1574, 105th Cong. (1998); H.R. 923, 105th Cong.
(1997); H.R. 922, 105th Cong. (1997); S. 368, 105th Cong. (1997).
132. See S. 1601, 105th Cong. (1998). The proposed act provides as follows:
Chapter 16--Cloning, Sec. 301: Prohibition on Cloning.
(a) In General-It shall be unlawful for any person or entity, public or
private, in or affecting interstate commerce, to use human somatic cell
nuclear transfer technology.
(b) ...
(c) ...
(d) Definition-The term 'human somatic cell nuclear transfer technol-
ogy' means taking the nuclear material of a human somatic cell and incor-
porating it into an oocyte from which the nucleus has been removed or
rendered inert and producing an embryo (including a preimplantation
embryo).
133. See J.P. Kassirer & N.A. Rosenthal, Should Human Cloning Research be
off Limits?, 338 New Eng. J. Med. 905, 905 (1998); see also Cannon & Haas, supra
note 7, at 642-43 (noting that pro-life groups such as National Right to Life Com-
mittee and the Christian Coalition, believe that human life begins when the egg is
fertilized. The groups oppose the bill because it fails to ban all research on the
fertilized egg. Some members of Congress believe the ban is overly broad, thus
regulating too many areas of research).
134. See Kassirer & Rosenthal, supra note 133, at 905 (arguing that both the
House and Senate bills would stop all cloning experiments with human cells).
135. See S. 1602, 105th Cong. (1998). The proposed act provides the following:
(b) Prohibitions-It shall be unlawful for any person or other legal entity,
public or private-
(1) to implant or attempt to implant the product of somatic cell nu-
clear transfer into a woman's uterus; ...
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planting an embryo into a woman's uterus using human cloning
procedures, but could permit research into cloning technologies to
clone molecules, cells and tissues.'3 6
B. Existing State Laws are Unable to Prohibit all Possible
Attempts at Human Cloning
Traditionally, states regulate medical procedures.137 Thus,
some argue that federal agencies should not regulate reproductive
techniques such as human cloning.' 38 However, the issue of
human cloning is larger than states' rights. The FDA has, on occa-
sion, intervened in states' rights to regulate medical procedures. 39
This is because the FDA has the knowledge and ability to test
these advanced medical procedures. 40 The FDA is superior com-
pared to the states in determining the safety of human cloning.
Although existing cloning bills vary from state-to-state, it still
remains to be seen whether states will have comprehensive bills to
regulate human cloning. Laws regulating research and/or experi-
mentation on embryos, fetuses or unborn children must include
comprehensive language encompassing early stage embryos, such
as would be used in cloning a human. 141 Today, only ten states use
(c) Protected Research and Practice-Nothing in this section shall be con-
strued to restrict areas of biomedical and agricultural research or practice
not expressly prohibited in this section, including research or practices
that involve the use of-
(1) somatic cell nuclear transfer or other cloning technologies to clone
molecules, DNA, cells, and tissues:
(2) mitochondrial, cytoplasmic or gene therapy; ....
136. See Kassirer & Rosenthal, supra note 133, at 905.
137. See Andrews, supra note 1, at 669.
138. See generally Cannon & Haas, supra note 7 (discussing the ethical dilem-
mas associated with the regulation of human cloning).
139. See Arthur L. Caplan, Why the Rush to Ban Cloning, N.Y. Times, Jan. 28,
1998, at A25, available in 1998 WL 5395773. The FDA has recently created the
Recombinant DNA Advisory Committee (RAC), an advisory body that will deter-
mine the safety of gene therapy before it is used on humans. See Susan M. Wolf,
Human Cloning: The Trouble with a Ban (visited Oct. 27, 1998) <http-//www.law.
umnn.edu/alumninews/spring98/human cloning.htm>.
140. See generally FDA Proposal, supra note 12. This guideline proposal regu-
lates technical manipulation of cells and genes.
141. See Andrews, supra note 1, at 658 n.107; See Fla. Stat. § 390.0111(5)
(1997); La. Rev. Stat. Ann. § 9:121-:122 (West 1991); Me. Rev. Stat. Ann. tit. 22,
§ 1593 (West 1992); Mass. Gen. Laws Ann. ch. 112, § 12J (West 1996); Mich.
Comp. Laws Ann. § 333.2685-.2692 (West 1992); Minn. Stat. § 145.421-.422 (1994);
N.D. Cent. Code § 14-02.2-01 to 14-.02.2-02 (1991); N.H. Rev. Stat. Ann. § 168-B:15
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such language in their laws. Some state laws regulating embryo
management could restrict even privately funded attempts at
human cloning, if cloning is considered to be a form of
fertilization. 142
In addition to state laws regulating research on embryos and
assisted reproductive techniques, as of December 7, 1999, nineteen
states introduced bills to ban human cloning. 143 Alabama, Califor-
nia, Illinois, New Jersey, New York, North Carolina, Oregon, and
West Virginia have introduced bills banning the cloning of an en-
tire individual regardless of the funding source.'44 Other states
have bills that specifically ban any research using cloned cells or
tissue (California and Florida); ban the use of governmental funds
for cloning an entire individual (Missouri and Maryland); or may
unintentionally ban beneficial research using cloned human tissue
or cells not intended for the creation of a child (South Carolina and
New York).145 Alabama proposed a bill banning governmental
funds for research involving cloned cells or tissue. Additionally,
Alabama proposed another bill that would ban cloning an entire
individual with or without federal or state funding. 46 Thus, the
inconsistency among state human cloning bills reinforces the need
for FDA regulation.
(1994); Pa. Cons. Stat. Ann. § 3216 (West Supp. 1998); R.I. Gen. Laws § 11-54-1
(1994).
142. See NBAC Report, supra note 5, at 89.
143. See S.B. 68, 1998 Reg. Sess. (Ala. 1998), S.B. 8, 1998 Reg. Sess. (Ala.
1998); H.B. 5475, 1998 Reg. Sess. Gen. Assembly (Conn. 1998); S.B. 241, 139th
Gen. Assembly, 2d Sess. (Del. 1998); H.B. 3206, 19th Leg. (Haw. 1998); S.B. 1243,
90th Gen. Assembly, 1997-98 Reg. Sess. (Ill. 1998); S.B. 825, 1999 Reg. Sess. (La.
1999); H.B. 2235, 90th Gen. Assembly, 1997-98 Reg. Sess. (Md. 1998); H.J.R. 11,
1998 Reg. Sess. (Md. 1998); S.B. 2423, 80th Reg. Sess. (Md. 1998); H.B. 2730, 80th
Reg. Sess. (Minn. 1998); H.B. 996, 1998 Reg. Sess. (Miss. 1998); H.B. 1658, 155th
Sess., 2d Year (N.H. 1998); A.B. 329, 208th Leg. (N.J. 1998); A.B. 2849, 207th Leg.
(N.J. 1997); S.B. 5993, 221st Leg. Sess. (N.Y. 1998); A.B. 9183, 221st Leg. Sess.
(N.Y. 1998); S.B. 2877, 220th Leg. Sess. (N.Y. 1997); H.B. 675, 122d Gen. Assem-
bly, 1997-98 Reg. Sess. (Ohio 1998); S.B. 218, 122d Gen. Assembly, 1997-98 Reg.
Sess. (Ohio 1998); H.B. 2128, 182d Gen. Assembly, 1997-98 Reg. Sess. (Pa. 1998);
H.B. 7123, 1997-98 Leg. Sess. (R.I. 1998); H.B. 3617, 112th Gen. Assembly Sess.
(S.C. 1997); S.B. 2295, 100th Gen. Assembly (Tenn. 1998); H.B. 2281, 100th Gen.
Assembly (Tenn. 1998); H.B. 2198, 100th Gen. Assembly (Tenn. 1998); S.B. 2208,
100th Gen. Assembly (Tenn. 1998); H.B. 752, 1998 Sess. (Va. 1998).
144. See NBAC Report, supra note 5, at 104. The states banning all cloning
attempts, regardless of the funding source, are Alabama, Illinois, New Jersey and
New York. See Andrews, supra note 1, at 660 n.121.
145. See NBAC Report, supra note 5, at 104.
146. See id.
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Also, technology is advancing faster than state legislation in
the area of reproductive technologies. Recent technological ad-
vances with animal embryo research may make much of the legis-
lation obsolete. 147 For example, researchers have placed DNA
from primates into cows' eggs that developed into early em-
bryos.148 If the same technique can produce normal human em-
bryos, then laws prohibiting the transfer of the nucleus into only a
human egg actually provide a legal loophole for doctors using do-
nor cow eggs. 149 Essentially, doctors would be able to transfer the
human nucleus into the cow's egg and then implant the cow's egg
into a human. FDA regulation would provide much-needed, up-to-
date legislation of reproductive technology (notwithstanding inevi-
table technological advances).
FDA should also regulate human cloning because state legisla-
tors suffer from a bane ignorance of human cloning. This igno-
rance produces proposed state bills with significant drafting
weaknesses. Five of these bills prohibit the cloning of a "geneti-
cally identical person."150 Statutes that prohibit the cloning of a
genetically identical person would not apply to human cloning,
since the clone would not be exactly identical to its donor. 151 The
cloned child's DNA would be differentiated differently from the
clone's donor DNA, because of variations in the conditions of the
mother's uterus and mother's mitochondrial DNA present inside
her egg cells. 152
While these state bills and regulations are a step in the right
direction, they are poor substitutes for a uniform federal law regu-
lating cloning. The state regulations have too many hidden weak-
nesses; thus, as an agency experienced in medical procedures, the
FDA should use its authority to create a uniform regulation for
human cloning. The next section considers in detail why both the
federal and state regulations, presently in place, are insufficient.
147. See Andrews, supra note 1, at 660-61.
148. See id.
149. See id. at n.122 (revealing Illinois, Kansas, New York, South Carolina, and
Tennessee as the five states and describing how the current technique uses a
donated egg that carries mitochondrial DNA from the enucleated egg;, thus the
clone will not be genetically identical to the original individual).
150. Id.
151. See id.
152. See id.
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C. Existing Agencies are Insufficient to Regulate Human
Cloning
One federal agency, the Department of Health and Human
Services (DHHS), which usually protects embryos and pregnant
women from risky, new research, lacks the authority to regulate
cloning. 153 The DHHS requires that researchers receive informed
consent from pregnant women, the approval of institutional review
boards and perform prior studies on animals to show that their
research poses only minimal risk to the fetus.'5 4 However, the
153. See Jonathan F.X. O'Brien, Cinderella's Dilemma: Does the In Vitro Stat-
ute Fit? Cloning and Science in French and American Law, 6 Tul. J. Int'l & Comp.
L. 525, 536 (1998) (citing 45 C.F.R. §§ 46.201-46.211 (1996)) (arguing that before
Dolly, the only way the federal government could dissuade scientists from perform-
ing research on embryos was by restricting funding). 45 C.F.R. § 46.201 (Applica-
bility) states: (a) The regulations in this subpart are applicable to all Department
of Human Health and Human Services grants and contracts supporting research,
development, and related activities involving- (1) the fetus, (2) pregnant women,
and (3) human in vitro fertilization. 45 C.F.R. § 46.201 (1997).
154. See O'Brien, supra note 153, at 536 (citing 45 C.F.R. §§ 46.201-46.211
(1996)). 45 C.F.R. § 46.207 (Activities Directed Toward Pregnant Women as Sub-
jects) states:
(a) No pregnant woman may be involved as a subject in an activity cov-
ered by this subpart unless:
(1) The purpose of the activity is to meet the health needs of the
mother and the fetus will be placed at risk only to meet such needs, or
(2) the risk to the fetus is minimal.
(b) An activity permitted under paragraph (a) of this section may be con-
ducted only if the mother and father are legally competent and have
given their informed consent after having been fully informed regarding
possible impact on the fetus ....
45 C.F.R. § 46.205 (Additional duties of the Institutional Review Boards in Con-
nection with Activities Involving Fetuses, Pregnant Women, or Human In Vitro
Fertilization) states:
(a) In addition to the responsibilities prescribed for Institutional Review
Boards under Subpart A of this part ....
(2) Determine that adequate consideration has been given to the man-
ner in which potential subjects will be selected, and adequate provi-
sions has been made by the applicant or offeror for monitoring the
actual informed consent process ....
(3) Carry out such other responsibilities as may be assigned by the
Secretary.
45 C.F.R. § 46.206 (General Limitations) states:
(a) No activity to which this subpart is applicable may be undertaken
unless:
(1) Appropriate studies on animals and nonpregnant individuals have
been completed;
(2) Except where the purpose of the activity is to meet the health
needs of the mother or the particular fetus, the risk to the fetus is
1999]
298 ROGER WILLIAMS UNIVERSITY LAW REVIEW [Vol. 5:273
DHHS's enabling statute fails to grant the DHHS the authority to
regulate cloning because the statute protects against embryo ma-
nipulation only after the embryo is a viable fetus. 155 Cloning a
human involves the manipulation of cells before the embryo is cre-
ated; the cells are not manipulated again. 156 The DHHS does not
protect an embryo until it is considered a viable fetus (fourteen
days after conception); at that point, the risks to the human clone
have already occurred. Thus a cloned embryo may continue to be
manipulated until implantation in the uterus because only then is
it considered a viable fetus. 57 Therefore, the FDA must protect
embryos from the hazards of cloning because the DHHS lacks the
authority to do so.
If the FDA fails to regulate human cloning, then the United
States must rely on a hodgepodge of state human cloning laws as
the primary means for regulating clinical applications of the tech-
nology. The proposed state bills on human cloning reveal tremen-
dous differences, with many of these states still awaiting FDA or
Congressional action for guidance and uniformity.
IV. FDA's AUTHORITY TO REGULATE HUMAN CLONING
The FDA has the authority to regulate human cloning under
section 351 of the Public Health and Service Act.' 58 However, to
fully comprehend how the FDA can regulate human cloning, one
must understand the history of the FDA's authority to regulate bi-
minimal and, in all cases, is the least possible risk for achieving the
objectives of the activity.
155. See O'Brien, supra note 153, at 536 (citing 45 C.F.R. § 46.201(a) (1996)).
156. See id. (citing 45 C.F.R. § 46.209 (1996)). 45 C.F.R. § 46.209(c) (Activities
directed towards fetuses ex utero, including nonviable fetuses, as subjects) states
"[i]n the event the fetus ex utero is found to be viable, it may be included as a
subject in the activity only to the extent permitted by and in accordance with the
requirements of other subparts of this part." 45 C.F.R. § 46.209 (1997). The fertil-
ized egg cell (embryo) is not considered a viable fetus until fourteen days after
fertilization; thus an egg manipulated and fertilized via cloning would not be con-
sidered a fetus before being put into the uterus. See O'Brien, supra note 153, at
536 n.86.
157. See id.
158. If a person were to attempt cloning a human being in violation of section
351 of the Public Health and Service Act, that person could be punished by a $500
fine and up to one year imprisonment. See 42 U.S.C. § 262(f) (1997). If cloning is
considered "an imminent or substantial hazard to the public health.. .," the per-
son could also be charged with a civil penalty of up to a $100,000 per day. 42
U.S.C. § 262(dX2XB) (1997).
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ological products. Over the years, Congress has given the FDA in-
creasing authority to regulate public health. In 1972, Congress
gave the FDA the job of regulating biological products under sec-
tion 351, which covers health concerns, including the control of
communicable diseases.15 9
To regulate human cloning under section 351 of the Public
Health and Services Act, the FDA must meet a two-part test. The
FDA must prove that human cloning falls: (1) within the definition
of a biological product and (2) under its proposed regulations of cell
and tissue-based products.160 Human cloning falls under the defi-
nition of a biological product because the cells and tissues are
"manipulated extensively [and] combined with non-tissue compo-
nents ... other than their normal functions." 16 1 Recently, the FDA
announced that it had classified human cloning as a form of cellu-
lar genetic therapy that fits within the FDA's cellular and tissue-
based products proposal; therefore the FDA considers a cloned em-
bryo a biological product. 162
A. Human Cloning as a Biological Product
At first glance, the FDA may appear to lack the authority to
regulate biological products in the area of reproductive technolo-
gies, such as human cloning. For many years, the FDA failed to
regulate reproductive tissue (semen and ova) as biological products
because at that time the states regulated reproduction.. 63 How-
ever, in 1997, the FDA demonstrated its ability to revise its au-
thority over biological products. In order to protect public health,
the FDA began regulating human tissue banks.' 64 This rationale
sets forth that "broad agency discretion is consistent with the
FDA's responsibility to protect the public health," courts generally
allow the FDA great discretion to interpret statutory language gov-
159. See Kevin L. Ropp, Just What is a Biologic, Anyway?, FDA Consumer, Apr.
1, 1993, at 27, 30.
160. See FDA Proposal, supra note 12, at 6.
161. Id.
162. See Weiss, supra note 10, at Al.
163. See Martha A. Wells, Overview of FDA Regulation of Human Cellular and
Tissue-Based Products, 52 Food & Drug L.J. 401, 402 (1997).
164. See Marc. 0. Williams, The Regulation of Human Tissue in the United
States: A Regulatory and Legislative Analysis, 52 Food & Drug L.J. 409, 411-12
(1997) (stating that the FDA regulates organs such as hearts and livers under the
PHS Act, because organs are analogous products to blood and blood products).
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erning the classification of products. 165 Since the courts give the
FDA this discretion, the FDA has the authority to include the ge-
netically manipulated reproductive tissue used in human cloning
within its definition of biological products. 16 6
In 1902, the original federal definition of biological products
included only vaccines and blood products. 167 However, today's
definition of a biological product has two broad components: "(1) it
must be a 'virus, therapeutic serum... or analogous product' and
(2) it must be 'applicable to the prevention, treatment, or cure of
diseases or injuries to man.'" 168 Still, the egg cell (human embryo),
duplicated through the cloning procedure, is an "analogous prod-
uct" as stated in the above-mentioned definition. The next subsec-
tion addresses the reasons why cloning is an analogous product to
those products specifically listed as biological products in section
351 of the PHSA.
For the FDA to regulate human cloning, the embryo manipu-
lated during the cloning procedure must be considered a biological
product as defined in section 351 of the Public Health and Service
Act (PHSA).169 According to Michael Beatrice, of the FDA's Center
for Biologics Evaluation and Research, "[ylou have to look at the
source [of a product] and the intended use, to determine if a prod-
uct is a biological product" suitable for treatment of a disease.' 7 0
When looking at the creation of an embryo through the process of
human cloning, the source of the original embryo is a human prod-
165. Jennifer Kulynych, Blood as a Biological "Drug": Scientific, Legal, and
Policy Issues in the Regulation of Placental and Umbilical Cord Stem Cell Trans-
plantation, 32 U. Rich. L. Rev. 407, 418 (1998).
166. See Andrews, supra note 1, at 657-58.
167. See Jodi K. Fredrickson, Umbilical Cord Blood Stem Cells: My Body
Makes Them, But Do I Get to Keep Them? Analysis of the FDA Proposed Regula-
tions and the Impact on Individual Constitutional Property Rights, 14 J. Cont.
Health L. & Pol'y 477, 482-83 (1998) (citing William R. Pendergast, Biological
Drugs, in Food and Drug Law 306-08 (Richard M. Cooper ed. 1991)). In 1902, the
Virus-Toxin Law brought biological products under federal regulatory control. See
Ropp, supra note 159, at 27.
168. Price, supra note 20, at 639 (quoting the Public Health and Service Act, 42
U.S.C. § 262(a) (1997)).
169. Biological products include "any virus, therapeutic serum, toxin, antitoxin,
vaccine, blood, blood component, or derivative, allergenic product, or analogous
product or arsphenamine or its derivative (or any other trivalent organic arsenic
compound), applicable to the prevention, treatment, or cure of diseases or injuries
of man." Public Health and Service Act, 42 U.S.C. § 262(i) (1998).
170. Ropp, supra note 159, at 28 (emphasis added).
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uct. However, in order to clone a child, that embryo must be more
than minimally manipulated. Thus, the creation of an embryo,
through the process of human cloning, falls into the biological
product category. 171 A human embryo is not considered to be a
"product" because an embryo is not typically "something pro-
duced."172 Congress could not have anticipated such biological in-
novations to create an all-inclusive definition of biological
products.173 As such, the definition can include human cloning as
a modern day biological product.
1. Human Cloning, an Analogous Product
The human egg cell, when genetically manipulated and manu-
factured in a laboratory through a cloning procedure, is an "analo-
gous product" to a live, whole cell vaccine under the PHSA because
the cloned embryo passes the first prong of the biological product
test.174 A cloned embryo, like a live vaccine originates from a liv-
ing entity and lives after manipulation. 75
Professor Elizabeth Price challenges the FDA's authority to
regulate cloning under section 351 of the Public Health and Ser-
vice Act based on the distinction between a biological entity and a
biological component. Price argues that the genetically manipu-
lated egg cell develops into "a complete biological entity onto itself'
as the embryo.' 76 She is under the belief that a human embryo
could never be analogous to a laboratory-created vaccine because a
vaccine is just a biological component and not "a complete biologi-
cal entity onto itself."177 However, her analysis ignores the fact
that "whole cell vaccines and microorganisms" may similarly be
considered "a complete biological entity onto itself."178
171. See FDA Proposal, supra note 12, at 7.
172. Ropp, supra note 159, at 29-30.
173. See id.
174. A bacterial cell is a prokaryotic cell which reproduces by dividing in half
through a process called binary fission. See Campbell, supra note 28, at 222. "Live
bacterial vaccines include the orally administered live, attenuated S.typhi strain
Ty2la vaccine for typhoid; the bacille Calmette-Gudrin (BCG) vaccine for tubercu-
losis, which consists of an attenuated strain of Myco-bacterium bovis; and an atten-
uated tularemia vaccine." Patrick R. Murray et al., Medical Microbiology 130-31
(3d ed. 1998).
175. See Stolberg, supra note 13.
176. Price, supra note 20, at 639.
177. Id.
178. Id.
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The FDA regulated whole cell vaccines and microorganisms in
the past; they were more than mere "biological components," they
were the whole "biological entity." 7 9 Many vaccines have used a
whole cell to carry out a biological function when in use.' 80 A
whole cell vaccine, such as a live bacterial vaccine, is a living, self-
sustaining cell that has the ability to reproduce itself.'18 Like a
cell vaccine, a scientifically developed human egg has the same re-
productive capabilities.
Genetically developed human egg cells are analogous to cell
vaccines. Cloning is a creation of a human embryo that would
otherwise not occur in nature. Unlike other assisted reproductive
techniques, such as IVF and intracytoplasmic sperm injections
(ICSI)'8 2 that require the egg and sperm cell's genetic material to
go through meiosis,'8 3 cloning eliminates this stage.1i 4 Meiosis is
a very important stage of human development because during mei-
osis, the female and male's DNA are crossed over each other and a
mixing of genes occurs.'1s The crossing over of genes is nature's
way of ensuring genetic variation in every generation.' 8 6 Elimi-
nating meiosis from human reproduction creates a human without
nature's genetic swap. Thus, the cloned embryo, like a whole cell
179. "This category comprises products derived from living materials-
humans, plants, animals, or microorganisms-when such products are used in the
treatment or prevention of disease." Kulynych, supra note 165, at 421 (citing
statement by Michael Beatrice of the FDA's Center for Biologics Evaluation and
Research (CBER), in Kevin L. Ropp, Just What is a Biologic, Anyway?, FDA Con-
sumer, Apr. 1, 1993, at 27). In 1902 when Congress created the definition of bio-
logics, "the word virus could refer to what are now recognized as a variety of
disease-causing microorganisms, including viruses, bacteria and protozoa." Ropp,
supra note 159, at 28 (emphasis added).
180. Hurly v. Lederle Lab., 651 F. Supp. 993, 995-96 (E.D. Tex. 1986) (noting
that the FDA regulated whole cell vaccines under the PHSA).
181. See Murray, supra note 174.
182. Scientists use intracytoplasmic sperm injections to inject sperm into the
egg cell. See N.Y. Task Force, supra note 11, at 64. This procedure still requires
the egg's genetic material and sperm's genetic material to go through meiosis and
the process of crossing over, which allows for a mixing of both cell's genes.
183. Meiosis is a crucial part of development that contains numerous steps.
This section will cover only a few pertinent steps. During Meiosis both the fe-
male's and male's chromosomes combine to form a nuclei, and segregation, cross-
ing over, and reassortment of the genes occurs. See Curtis, supra note 51, at 249.
184. See Corsover, supra note 26, at 706-07.
185. See Curtis, supra note 51, at 984.
186. See id.
19991 DECONSTRUCTING THE HUMAN EGG 303
vaccine, is a biological product, created from human egg cell
manipulation.
The genetically manipulated human egg cell is an analogous
product to those products listed in the PHSA definition of biological
products. Thus, the FDA could regulate a genetically manipulated
embryo as an "analogous product" 87 of a whole cell vaccine, which
would fall within section 351 of the PHSA. However, the FDA
must also demonstrate that human cloning may represent a treat-
ment for the disease of infertility.
2. Cloning's Application to Disease Prevention
Human cloning must also be "applicable to the prevention,
treatment, or cure of diseases or injuries to man."i s8 Thus, the
first issue to address is whether human infertility is indeed, a dis-
ease. Until recently, courts have split on whether infertility should
be viewed as a malfunction or illness of the human body.' 8 9 The
United States Supreme Court put an end to this split in Bragdon v.
Abbott' g viewing infertility as a disease or a disorder of the
human body. 19 Thus, one could view human cloning as a possible
treatment and a cure for the disease of infertility.
187. The courts will likely allow regulation of cloning as an "analogous product"
because they have given the FDA great deference in the past to determine what it
considers to be an "analogous product" of a virus, serum, toxin, or antitoxin.
United States v. Calise, 217 F. Supp. 705, 708-09 (S.D.N.Y. 1962) (holding that:
if defendants were true in their claim that blood cannot be 'propagated' or
'manufactured and prepared' except in the body of a person, and that
therefore blood cannot be one of the products to which Congress intended
the licensing statute to apply, then nothing which is ultimately derived
from nature would ever be capable of subsequently being 'manufactured
and prepared'. The word 'manufactured' as employed in this statute obvi-
ously was intended to include 'processing' within its signification).
188. 42 U.S.C. § 262(h)(1) (1998).
189. Compare Erickson v. Board of Governors, 911 F. Supp 316 (N.D. Ill. 1995),
and Pacourek v. Inland Steel Co., 916 F. Supp. 797 (N.D. Ill. 1996) (holding that
infertility is a disability because it is a major physical impairment that substan-
tially limits life activities), with Zatarain v. WSDU-Television, Inc., 79 F.3d 1143
(5th Cir. 1996), and Krauel v. Iowa Methodist Med. Ctr., 95 F.3d 674 (8th Cir.
1996) (holding that reproduction is not a major life activity).
190. 524 U.S. 624 (1998).
191. See id. at 637-39 (holding that HIV's inhibiting affect over reproduction is
a disability because reproduction is a "major life activity" and infertility obviously
"substantially limits" this activity); see also Egert v. Connecticut Gen. Life Ins. Co.,
900 F.2d 1032, 1038 (7th Cir. 1990) (holding that artificial insemination and 1VF
are treatments for infertility despite the fact that such therapies do not correct the
underlying problem). The ADA defines a "physical or mental impairment" as a
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The second issue to address is whether human cloning will ac-
tually prevent, treat or cure this disease. In several cases, insur-
ance companies have argued that assisted reproductive
techniques, such as IVF and artificial insemination, do not treat
infertility because the procedures do not cure the underlying dis-
ease.' 9 2 In Egert v. Connecticut General Life Insurance Co.,' 9 3 the
insurance company stated that it would cover treatments for
blocked fallopian tubes but not IVF.'9 4 The Seventh Circuit held
that the insurance company would have to pay for the IVF treat-
ments because infertility is an illness and IVF is a viable treat-
ment.195 Human cloning will treat this disease because it enables
infertile people to have children, through the use of a genetically
manipulated embryo (a biological product). Thus, the cloned em-
bryo is a biological product, which will treat the disease of
infertility.
Some scholars doubt the value of cloning as a treatment for a
disease. In particular, Professor Elizabeth Price discounts the
"treatment" merit of cloning.' 96 The flaw in Price's argument is
the way in which she frames the question of disease. Instead of
considering whether infertility is a disease, she asks whether preg-
nancy is a disease. 197 While cloning is not a treatment for preg-
nancy, it may be a possible treatment for infertility. Had Price
framed the disease at issue as infertility, she would have reached
the conclusion that cloning is a viable treatment.
As aforementioned, the embryo used in cloning is a biological
product. Since it is a biological product and it will effectively treat
the disease of infertility, the FDA has jurisdiction to regulate clon-
ing through its regulations of biological products under section 351
of the PHSA.
condition affecting one or more of a number of listed "body systems" with a specific
reference to the reproductive system. 29 CFR Part 1630.2(h)(1) (1995). The Amer-
ican Society for Reproductive Medicine defines infertility as a disease that exists
when a couple has tried to conceive for 12 months, without the use of contracep-
tives. See American Society for Reproductive Medicine, Guidelines for the Provi-
sion of Infertility Services (visited Oct. 2, 1999) <http://www.asrm.com>.
192. See Witcraft v. Sunstand Health and Disability Group Beftefit Plan, 420
N.W.2d 785 (Iowa 1988); Egert, 900 F.2d at 1038.
193. 900 F.2d 1032, 1038 (7th Cir. 1990).
194. See id.
195. See id.
196. See Price, supra note 20, at 640.
197. See id.
DECONSTRUCTING THE HUMAN EGG
B. Does the FDA's Cellular and Tissue-Based Proposal Cover
Human Cloning?
In February 1997, the FDA published its first guidance docu-
ment to propose new regulations for human cellular and tissue-
based products.' 98 The FDA has never had a formal regulatory
program for human cellular and tissue-based products; instead it
has regulated these products on a case-by-case basis.' 99 Through
its proposal to regulate cell and tissue-based products the FDA in-
tended to: 1) prevent the use of contaminated tissue; 2) prevent
mishandling that might cause contamination of the tissue; and 3)
ensure clinical safety for tissue that is more than minimally
manipulated. 200 The FDA determined that it would regulate tis-
sues based on degree of risk, source, use and the necessity for FDA
review.20
As noted above, the FDA believes human cloning is a form of
cell/gene therapy, which involves the manipulation of human tis-
sue, thus requiring FDA approval. The FDA determined that the
kind of manipulation involved in human cloning presents "'serious
health and safety issues'" for the fetus and the mother.20 2 To un-
derstand why the FDA believes human cloning falls within its reg-
ulatory authority, one must understand the FDA's proposed
regulations of cellular and tissue-based products. The FDA's pro-
posed guidance document explains the regulation of human tissue
and covers reproductive tissues that are minimally manipulated
and used for their normal functions.20 3 In determining whether
human cellular tissue based products fall within its proposal the
FDA considers: 1) whether donor or non-donor tissue is required
for cloning procedures and 2) whether the procedure requires more
198. See FDA Proposal, supra note 12.
199. See Wells, supra note 163, at 405. "[Tjhe term 'human cellular and tissue-
based products' encompasses an array of medical products derived from the human
body and used for replacement, reproductive, or theraputic purposes .... Semen,
ova, and embryos are transferred for reproductive purposes." Establishment Re-
gistration and Listing for Manufactures of Human Cellular and Tissue-Based
Products, 63 Fed. Reg. 26,744 (1998).
200. See FDA Proposal, supra note 12, at 6.
201. See Establishment Registration and Listing for Manufactures of Human
Cellular and Tissue-Based Products, 63 Fed. Reg. 26,745 (1998).
202. Price, supra note 20, at 619 (quoting Rick Weiss, Human Clone Research
Will Be Regulated, Wash. Post, Jan. 20, 1998, at Al, available in 1998 WL
2462936).
203. See FDA Proposal, supra note 12, at 6.
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than minimal manipulation of cells and tissue.20 4 However, the
proposal's distinction between non-donor and donor tissue creates
a loophole that defeats one of the original intentions of the
proposal.
1. Human Cloning Within FDA Regulation of Donor Tissue
(Allogeneic Tissue versus Autologous Tissue)
Human cloning carries the risk of transmitting communicable
disease because cellular or tissue-based products are used.20 5 The
FDA believes that the transfer of reproductive tissue poses limited
harm to the recipient, therefore the FDA is only concerned with
reproductive tissue when it comes from a donor.20 6 The FDA be-
lieves that the level of public health concern for semen, eggs and
embryos depends on whether they are obtained from a sexually in-
timate partner of the transplantlinsemination recipient or from do-
nors that might spread communicable diseases.20 7 The FDA only
recommends that autologous stem cells20 or cells taken from inti-
mate sexual partners be screened before clinical use.20 9 In gen-
eral, the transfer of reproductive tissues such as semen and eggs,
obtained from the recipient's partner or the same person poses less
risk to the recipient's health. Tissue rejections among recipients
having prior exposure to each other and to the risk of disease from
that partner posses a lessor degree of danger to the recipient.210
Therefore, in the guidance document, only allogeneic211 living
somatic cells which have been manipulated would require screen-
ing before clinical use.21 2 A person may use tissue that has under-
gone more than minimal manipulation if the tissue is autologous
204. See id. at 7.
205. See id. at 12.
206. See Establishment Registration and Listing for Manufactures of Human
Cellular and Tissue-Based Products, 63 Fed. Reg. 26,750 (1998).
207. See Establishment Registration and Listing for Manufactures of Human
Cellular and Tissue-Based Products, 63 Fed. Reg. 26,745 (1998).
208. Autologous stem cells are cells or tissues used in the same person from
whom they were obtained. See FDA Proposal, supra note 12, at 29.
209. See id. at Table I.
210. See Establishment Registration and Listing for Manufactures of Human
Cellular and Tissue-Based Products, 63 Fed. Reg. 26,750 (1998).
211. Allogeneic cells are cells or tissue used in a different person from whom
they were obtained. See FDA Proposal, supra note 12, at 29. The term Allogeneic
cells does not include reproductive cells and tissues from sexually intimate part-
ners of the intended recipient. See id. at 12.
212. See id. at Table I.
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reproductive tissue or tissue from an intimate sexual partner,
without filing an investigational new drug application (IND).2 13
This distinction (within the FDA's proposal) fails to give the FDA
sufficient authority to regulate cloning because the FDA would not
regulate such reproductive tissue even if the tissue has been more
than minimally manipulated.214 The proposal would only allow
the FDA to regulate cloning in situations where an infertile woman
needs a donor egg cell, or where a female is not willing to use her
own DNA and needs DNA from a donor.215 FDA authority is inva-
lid in situations similar to that of Richard Seed, where a couple
does not require the help of donated reproductive tissue.21 6 If the
FDA does not change this distinction, human cloning could still oc-
cur even with FDA regulation under its cell and tissue proposal.
Next, one must define the FDA's standard of manipulation to
determine if donor tissue used in cloning is more than minimally
manipulated and falls under the FDA proposal's regulatory
requirements.
2. Standards of Manipulation
The FDA should regulate donor cells and tissue used in
human cloning, which unlike IVF and ICSI, requires more than
minimal manipulation of cells and tissue.217 The more than mini-
mal manipulation standard is of great significance to the FDA be-
cause it differentiates human tissue experiments that do and do
not require prior approval. 218 The definition of manipulation is a
measure of the extent to which the biological characteristics of a
213. See id. This filing process, if applied to human cloning attempts, would
require researchers to prove to the FDA's satisfaction that their proposed experi-
ments do not pose unreasonable risk of harm to human subjects. See Price, supra
note 20, at 620-21 (stating that this process is identical to the IND application that
drug companies must file when they want to conduct human trials to test new
medicines. Both of these therapies use IND's applications, the same as described
for any investigational biological product in 21 C.F.R. 312.23).
214. See Price, supra note 20, at 620.
215. See Andrews, supra note 1, at 658 (citing FDA, Proposed Approach to Reg-
ulation of Cellular and Tissue-Based Products 6, 9 (1997)).
216. See Dizon, supra note 8.
217. See NBAC Report, supra note 5, at 32.
218. See Establishment Registration and Listing for Manufactures of Human
Cellular and Tissue-Based Products, 63 Fed. Reg. at 26,748 (1998).
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tissue have been changed.219 Therefore, minimal manipulation is
when the processing does not alter the original relevant character-
istics of the cell or tissue.220 Examples of minimal manipulation
include the cutting, grinding, shaping, separating, cryopreserva-
tion,221 and freezing of cells and tissues.222 More than minimal
manipulation is "when the processing alters the biological charac-
teristics (and potentially the functional integrity) of those cells or
tissue, or when adequate information does not exist to determine
whether the processing will alter the biological characteristics of
the cell or tissue."223 Examples of more than minimal manipula-
tion include "cell expansion, encapsulation, activation, or genetic
modification."224 Also, the FDA might consider a minimal tissue
product to be more than minimally manipulated if it is used by a
large number of patients or is very risky and harmful. 225
The process of human cloning, which requires more than mini-
mal manipulation, would involve the transfer of a cell nucleus from
an adult cell into a denucleated egg (an egg without a nucleus). 226
Human cloning is not just the process of separating adult stem
cells2 2 7 from mature tissue, which the FDA considers to be mini-
mal manipulation. 228 Instead, human cloning is the genetic modi-
fication of the cell because the nucleus of the cell, which contains
the genetic material, is removed. The cell's genetic material differ-
219. See Mary Pendergast, FDA Outlines Possible Regulatory Scheme for Engi-
neered Tissue Products (visited Oct. 29, 1999) <http-/www.info@ptei.org/brochure/
government/FDAReg.html>.
220. See Establishment Registration and Listing for Manufactures of Human
Cellular and Tissue-Based Products, 63 Fed. Reg. at 26748 (1998).
221. Cryopreservation is a freezing process used on embryos, cells, tissues and
organs. See N.Y. Task Force, supra note 11, at 81.
222. See Establishment Registration and Listing for Manufactures of Human
Cellular and Tissue-Based Products, 63 Fed. Reg. 26,748 (1998); FDA Proposal,
supra note 12, at 16-17.
223. FDA Proposal, supra note 12, at 17.
224. Establishment Registration and Listing for Manufactures of Human Cel-
lular and Tissue-Based Products, 63 Fed. Reg. 26,748 (1998); see FDA Proposal,
supra note 12, at 16-17.
225. See Pendergast, supra note 219.
226. See NBAC Report, supra note 5, at 1. The denucleated egg cell is an egg
cell that has its nucleus removed. "Examples of more-than-minimal manipulation
include encapsulation, activation, [and] genetic modification." FDA Proposal,
supra note 12, at 17.
227. Adult stem cells are any cells other than reproductive cells.
228. See Establishment Registration and Listing for Manufactures of Human
Cellular and Tissue-Based Products, 63 Fed. Reg. 26,748 (1998).
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entiates the cell during cellular growth; replacing this genetic ma-
terial during human cloning alters the outcome of the cell after
differentiation. 229 The egg cell now has the parental cell's nucleus;
this nucleus triggers the transformation of the egg into an em-
bryo. 230 Thus, human cloning is a genetic modification of the cell
that requires more than minimal manipulation.
IVF, as compared to cloning, does not fall under the FDA stan-
dard of more than minimal manipulation. Therefore, the FDA can-
not regulate IVF under this proposal. There are six major
procedures during IVF: (1) ovarian stimulation; (2) egg collection;
(3) fertilization and embryo culture; (4) embryo transfer; (5) preg-
nancy; and, (6) delivery. 231 The second, third and fourth proce-
dures of IVF involve a needle puncture to remove the eggs, placing
the eggs and sperm in a petri dish which leads to fertilization, and
finally implanting the egg into the uterus through a catheter.232
In IVF procedures, no genetic manipulation occurs because sperm
fertilizes the egg and normal meiosis occurs. In human cloning,
however, the egg's nucleus is removed and replaced with another
nucleus, thereby changing the genetic make-up of the egg cell and
causing the egg to differentiate differently.
Human cloning also differs from intracytoplasmic sperm injec-
tion (ICSI), known as micromanipulation. 233 ICSI is another new
infertility technique that was used before it was proven safe for
children.234 ICSI, as noted above, allows doctors to inject the
sperm directly into the egg cell with minimal manipulation of the
egg's coating.235 But, the chromosomes of the egg and sperm cells
still undergo meiosis, which the cloning procedures eliminated.
229. See Andrews, supra, note 1, at 650.
230. See id.
231. See N.Y. Task Force, supra note 11, at 52.
232. See id. at 52-58; Nicole L. Cucci, Constitutional Implications of In Vitro
Fertilization Procedures, 72 St. John's L. Rev. 417, 421 (1998).
233. Micromanipulation is a procedure in which a single sperm is injected di-
rectly into an egg. See N.Y. Task Force, supra note 11, at 64.
234. See id. at 65 (citing J.J. Kurinczuk & C. Bower, "Birth Defects in Infants
Conceived by Sperm Injection: An Alternative Interpretation," 315 Brit. Med. J.
1260 (1997)). Some studies indicated that children born after ICSI are twice as
likely to have major congenital abnormalities and 50% more likely to have a minor
defect as compared to "natural births." Id.
235. See id. at 65 (stating that in this procedure, the egg cell is exposed to en-
zymes, heat, intense light and chemicals, but these exposures have not been
proven to cause genetic abnormalities) (citations omitted).
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This procedure only requires the injection of sperm into the nu-
cleus of the egg cell, which allows for meiosis to occur and causes
no genetic modification. Thus, ICSI does not involve more than
minimum manipulation, so the FDA has not been able to regulate
this procedure. 236 Although some people believe that the FDA
should not regulate cloning if it cannot regulate ICSI,237 cloning
involves much more manipulation of the egg cell than does ICSI,
therefore requiring a different standard of regulation.
Since cloning should be considered an "analogous product" of a
whole cell vaccine and is intended for the treatment of infertility,
the FDA has the authority to regulate it under section 351 of the
PHSA. The FDA, however, cannot fully regulate human cloning
because it has not included autologous tissue and reproductive tis-
sue from sexually intimate partners in the proposal. 238 Unless the
236. In her law journal article, Lori Andrews asked why the FDA did not regu-
late ICSI, "in which DNA (in the form of sperm) is being injected into women's
eggs?" Andrews, supra note 1, at 658 n.102. The answer is that, unlike in the
cloning procedure, the DNA injected into the egg cell in ICSI has not already differ-
entiated a cell. ICSI uses sperm DNA; the sperm's and egg's DNA go through nor-
mal sexual reproduction stages of meiosis and crossover. With human cloning, the
DNA is from an adult cell; this DNA does not go through meiosis when it is put
into an enucleated egg. Rather, the DNA differentiates the egg without ever
changing its genetic makeup. Therefore, ICSI does not involve more than mini-
mum manipulation of cells and tissues as occurs during cloning.
237. See id.
238. If used to regulate cloning, the FDA's current proposal could fall to consti-
tutional claims of Due Process because the FDA has failed to narrowly tailor its
proposal to ban all possible forms of human cloning. The possible benefits of
human cloning for infertile people raises constitutional issues of whether the FDA
has the authority to regulate a medical procedure possibly used for the treatment
of infertility. The Supreme Court established that the agencies' regulations in-
volving privacy and reproductive rights must pass "strict judicial scrutiny" to en-
sure that they do not violate the Fourteenth Amendment. Carey v. Population
Serv. Int'l, 431 U.S. 678, 688 (1977). Thus, any agency regulating reproductive
methods must satisfy a two-prong strict scrutiny test in order to pass Constitu-
tional muster. First, the agency's regulations must serve a compelling interest
and, second, the regulation must be narrowly tailored to further that interest. See
id.
The FDA's regulations on human cloning do not pass the strict scrutiny stan-
dard. Even though the regulations serve a compelling interest of protecting people
from a risky medical procedure, the regulations are not narrowly tailored accord-
ing to the criteria established in Carey v. Population Serv. Int'l. See id. The Court
declared that in order to be narrowly tailored to achieve its interests, a ban must:
(i.) be necessary, and (ii.) be geared to achieve its goal. See id. at 695-96. As it
stands now, the FDA's current proposal to regulation cloning is not narrowly tai-
lored, because of the distinction between autologous tissue, intimate sexual part-
ner tissue and allogeneic tissue. The FDA's proposal would only allow the agency
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FDA redefines its proposal of cellular and tissue-based products,
human cloning, with its potential health risks, will likely occur in
the private sector.
C. Possible Solutions to the Lack of Authority
Although one of the FDA's objectives, along with stopping the
spread of communicable diseases, is to ensure the clinical safety
and effectiveness of more than minimally manipulated tissue, the
FDA proposal allows for a high probability of children being born
with human cloning-caused deformities. 239 For the FDA to com-
pletely regulate human cloning, it would have to drop the autolo-
gous and intimate/sexual partners characterization of its guidance
proposal for genes and human tissue.240 This distinction stems
from the FDA's mistaken conclusion that reproductive tissue
transfer does not pose a significant risk to the health of recipients,
especially when the tissue is from that person or an intimate sex-
ual partner.24 1 The FDA may be correct in its belief that "the fail-
ure of a reproductive-tissue product will generally cause lesser
health risks to the individual than the failure of other systemic
products."242 However, the manipulated DNA of a cloned embryo
may have some risk of carrying genetic mutations, which could
cause the child to have deformities. As noted in Part I of this Com-
ment, an adult nucleus has already completed forty-five cell divi-
sions, and may have accumulated genetic disease and mutations,
which would be transferred upon implantation into an undifferen-
to ban human cloning from occurring in cases where donor tissue is necessary. See
Andrews, supra note 1, at 658 (citing Guidance Table I). The FDA's regulations
"do not require prior approval if a patient's cells are being used for his or her own
reproductive purposes." Id. Given its ability to regulate human cloning through
this proposal, the FDA could stop some couples (when the woman is infertile) from
using donated eggs in cloning. The proposal, however, would not allow the FDA to
restrict fertile couples and fertile individual women from using their own eggs in
cloning. Thus, the FDA must eliminate this distinction between autologous tissue
and intimate sexual partner to equally regulate human cloning and not violate the
Due Process Clause of the Fourteenth Amendment.
239. See FDA Proposal, supra note 12, at 6.
240. See id. at 20. Under the FDA's regulatory requirements, the autologous
cells and tissues (i.e. cells from the same person) would not be subject to any regu-
latory requirements.
241. See Establishment Registration and Listing for Manufactures of Human
Cellular and Tissue-Based Products, 63 Fed. Reg. 26,750 (1998).
242. Id.
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tiated egg cell. 243 The FDA should be concerned, not only about
the health of the reproductive-tissue recipient, but also with the
health of the children born through the cloning process.
If the FDA is truly concerned about "ensuring that clinical
safety and effectiveness is demonstrated for tissues that are highly
processed," then it should regulate a cloned embryo as a biological
product that could quite possibly cause great harm to the person
created from the procedure. The reproductive method of human
cloning has a high chance of producing genetic deformities because
the procedure creates an embryo from adult DNA that nature
never meant to differentiate an egg cell. 2 4 However, because the
FDA will not test more than minimally manipulated autologous
tissue to ensure safety and effectiveness, children with severe ge-
netic deformities could be born via cloning.245
Obviously, all expecting parents fear giving birth to a child
with a genetic deformity. Many people have tests done, such as
amniocentesis, to determine whether deformities exist in their un-
born children.246 So, why would the FDA permit a procedure that
is likely to cause many genetic deformities in children? The an-
swer seems to be that the risk for the recipient of reproductive tis-
sue is minimal when autologous tissue is used. However, this
illustrates how the FDA overlooks the fact that human cloning
could be as damaging to children as any disease.247 The FDA must
not ignore this fact because in doing so, they are guaranteeing that
many parents may face their worst nightmare, a child with a ge-
netic deformity. Both parents and child will now have to face a
lifetime of hardships (physically, emotionally, and financially)
243. See Andrews, supra note 1, at 650 (noting that "[a]ctivating the slumber-
ing genes may reveal hidden mutations").
244. See Annas, supra note 68, at 254 (stating that "[ciloning has nothing in-
herently to do either with infertile couples or natural twins because women would
be able to replicate themselves without male involvement... [alsexual cloning by
nuclear substitution represents such a discontinuity in the way humans
reproduce").
245. See Establishment Registration and Listing for Manufactures of Human
Cellular and Tissue-Based Products, 63 Fed. Reg. 26,750 (1998).
246. This procedure makes it possible for prenatal detection of Down's syn-
drome and many other genetic deformities present in the fetus. See Curtis, supra
note 51, at 387.
247. See supra note 58, at 2D (noting that, by trying to create new life from old
cells, clones "may be susceptible to premature aging and disease").
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which not only could have been prevented, but should have been
prevented.
Assuming arguendo that the FDA were to drop the distinction
between donor and non-donor tissue, then fertility clinics offering
human cloning would have to file an investigational new drug ap-
plication (IND) with the FDA, followed by a lengthy review. 248
This filing process, if applied to human cloning attempts, would
require researchers to prove to the FDA's satisfaction that their
proposed experiment does not pose unreasonable risk of harm to
human subjects. 249 The FDA can ask questions such as: "Have you
established animal models?; Can you improve the odds?; Have you
looked at safer alternatives?"250 Thus, the FDA's regulation would
help protect public health and safety and cause potential human
cloning researchers to contemplate their actions before placing
human beings in danger.
V. CONCLUSION
Human cloning presents potential health risks to people un-
dergoing this procedure. Until this cloning procedure is perfected,
men, women and children will be subjects of a dangerous experi-
ment, unless (1) scientists conduct animal research and (2) FDA
regulation continues. While the FDA has the authority to regulate
human cloning, the FDA's present regulations will not achieve the
agency's goals. With the rapid progress of modern science, human
cloning will inevitably occur in the near future. However, under
the FDA's proposal as it stands today, a cloned child can be made
without the FDA's consent, unless the FDA moves away from their
misconceived belief that reproductive tissue cannot harm humans.
Thus, it must drop the autologous and intimate/sexual partners
characterization of its guidance proposal for human cells and tis-
sue. Although the FDA's current regulations cannot completely
regulate against human cloning, the FDA does have the basis for
more strict regulation and, most importantly, the duty to preserve
the health and safety of our country's people.
B. Jason Erb
248. See Price, supra note, 20, at 620-21.
249. See id.
250. Weiss, supra note 10, at Al.
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